Dan Peer

List of Publications by Year
in descending order

148 papers	18,449 citations	30070 54 h-index	11939 134 g-index
160 all docs	160 docs citations	160 times ranked	24774 citing authors

#	Article	IF	Citations
1	Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2, 751-760.	31.5	7,469
2	Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 2018, 9, 1410.	12.8	1,488
3	Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target. Science, 2008, 319, 627-630.	12.6	475
4	Nanoparticle Hydrophobicity Dictates Immune Response. Journal of the American Chemical Society, 2012, 134, 3965-3967.	13.7	418
5	The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 2010, 31, 6867-6875.	11.4	384
6	Polysaccharides as building blocks for nanotherapeutics. Chemical Society Reviews, 2012, 41, 2623-2640.	38.1	339
7	CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances, 2020, 6, .	10.3	270
8	Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4095-4100.	7.1	262
9	Nanoparticles for Imaging, Sensing, and Therapeutic Intervention. ACS Nano, 2014, 8, 3107-3122.	14.6	255
10	Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. International Journal of Cancer, 2004, 108, 780-789.	5.1	215
11	Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Journal of Controlled Release, 2011, 156, 231-238.	9.9	204
12	Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in Syngeneic and Human Xenograft Mouse Tumor Models. Neoplasia, 2004, 6, 343-353.	5.3	197
13	A modular platform for targeted RNAi therapeutics. Nature Nanotechnology, 2018, 13, 214-219.	31.5	197
14	RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT Mice. Molecular Therapy, 2010, 18, 370-376.	8.2	192
15	Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nature Communications, 2018, 9, 4493.	12.8	190
16	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. Biomaterials, 2019, 223, 119486.	11.4	159
17	Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano, 2017, 11, 7572-7586.	14.6	158
18	Paving the Road for RNA Therapeutics. Trends in Pharmacological Sciences, 2020, 41, 755-775.	8.7	152

#	Article	IF	Citations
19	On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635.	31.5	149
20	RNAi-based nanomedicines for targeted personalized therapy. Advanced Drug Delivery Reviews, 2012, 64, 1508-1521.	13.7	147
21	Localized RNAi Therapeutics of Chemoresistant Grade IV Glioma Using Hyaluronan-Grafted Lipid-Based Nanoparticles. ACS Nano, 2015, 9, 1581-1591.	14.6	147
22	Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano, 2015, 9, 6706-6716.	14.6	146
23	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioengineering and Translational Medicine, 2021, 6, e10213.	7.1	142
24	Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials, 2010, 31, 7106-7114.	11.4	136
25	Special delivery: targeted therapy with small RNAs. Gene Therapy, 2011, 18, 1127-1133.	4.5	133
26	A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Advanced Materials, 2020, 32, e1906128.	21.0	126
27	Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Letters, 2015, 364, 59-69.	7.2	117
28	Altering the immune response with lipid-based nanoparticles. Journal of Controlled Release, 2012, 161, 600-608.	9.9	108
29	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied Nano Materials, 2020, 3, 10634-10645.	5.0	108
30	Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation. ACS Nano, 2017, 11, 5195-5214.	14.6	104
31	Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeuticsâ€"An innate immune system standpoint. Seminars in Immunology, 2017, 34, 68-77.	5.6	103
32	Principles for designing an optimal mRNA lipid nanoparticle vaccine. Current Opinion in Biotechnology, 2022, 73, 329-336.	6.6	102
33	Precision Nanomedicine in Neurodegenerative Diseases. ACS Nano, 2014, 8, 1958-1965.	14.6	95
34	Reshaping the Future of Nanopharmaceuticals: <i>Ad Iudicium</i>. ACS Nano, 2011, 5, 8454-8458.	14.6	90
35	Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models. Cancer Research, 2004, 64, 7562-7569.	0.9	86
36	Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. Advanced Materials, 2019, 31, e1803895.	21.0	85

#	Article	IF	Citations
37	Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics, 2020, 10, 938-955.	10.0	84
38	Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1612, 76-82.	2.6	80
39	Modulation of Drug Resistance in Ovarian Adenocarcinoma Using Chemotherapy Entrapped in Hyaluronan-Grafted Nanoparticle Clusters. ACS Nano, 2014, 8, 2183-2195.	14.6	80
40	Fluoxetine and reversal of multidrug resistance. Cancer Letters, 2006, 237, 180-187.	7.2	79
41	Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nature Nanotechnology, 2021, 16, 1030-1038.	31.5	78
42	Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Advanced Drug Delivery Reviews, 2012, 64, 1738-1748.	13.7	75
43	Omics-based nanomedicine: The future of personalized oncology. Cancer Letters, 2014, 352, 126-136.	7.2	75
44	Corneal gene therapy. Journal of Controlled Release, 2007, 124, 107-133.	9.9	74
45	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E16-22.	7.1	73
46	Modulation of Immune Response Using Engineered Nanoparticle Surfaces. Small, 2016, 12, 76-82.	10.0	71
47	Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials, 2011, 32, 4840-4848.	11.4	69
48	Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality. Bioconjugate Chemistry, 2016, 27, 855-862.	3.6	67
49	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered <i>via</i> Lipid Nanoparticles. ACS Nano, 2021, 15, 9627-9637.	14.6	66
50	Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Letters, 2013, 334, 221-227.	7.2	65
51	Overcoming multidrug resistance with nanomedicines. Expert Opinion on Drug Delivery, 2015, 12, 223-238.	5.0	61
52	Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale, 2014, 6, 3742-3752.	5.6	60
53	Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer and Metastasis Reviews, 2015, 34, 291-301.	5.9	58
54	A daunting task: manipulating leukocyte function with <scp>RNA</scp>i. Immunological Reviews, 2013, 253, 185-197.	6.0	55

#	Article	IF	Citations
55	Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Delivery and Translational Research, 2014, 4, 96-103.	5.8	52
56	AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13991-13996.	7.1	51
57	Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Letters, 2014, 354, 290-298.	7.2	51
58	Quaternized starch-based carrier for siRNA delivery: From cellular uptake to gene silencing. Journal of Controlled Release, 2014, 185, 109-120.	9.9	50
59	Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery. Nanotechnology, 2015, 26, 115101.	2.6	49
60	Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opinion on Drug Delivery, 2016, 13, 1573-1582.	5.0	46
61	Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Advanced Drug Delivery Reviews, 2020, 159, 364-376.	13.7	46
62	Treatment of resistant human colon cancer xenografts by a fluoxetineâ€"doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Letters, 2009, 274, 118-125.	7.2	43
63	Therapeutic mRNA delivery to leukocytes. Journal of Controlled Release, 2019, 305, 165-175.	9.9	43
64	RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology, 2010, 21, 232001.	2.6	42
65	Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis inÂvitro and inÂvivo. Molecular Therapy, 2021, 29, 2239-2252.	8.2	42
66	Physicochemical Evaluation of a Stability-Driven Approach to Drug Entrapment in Regular and in Surface-Modified Liposomes. Archives of Biochemistry and Biophysics, 2000, 383, 185-190.	3.0	40
67	Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Molecular Therapy, 2017, 25, 1491-1500.	8.2	40
68	Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. ACS Nano, 2020, 14, 4774-4791.	14.6	40
69	Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. Bioconjugate Chemistry, 2017, 28, 556-564.	3.6	39
70	Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. Journal of Controlled Release, 2019, 313, 33-41.	9.9	38
71	eIF3c: A potential therapeutic target for cancer. Cancer Letters, 2013, 336, 158-166.	7.2	33
72	Progress and challenges towards CRISPR/Cas clinical translation. Advanced Drug Delivery Reviews, 2020, 154-155, 176-186.	13.7	33

#	Article	IF	Citations
73	Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine, 2011, 6, 1771-1785.	3.3	32
74	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. Frontiers in Immunology, 2017, 8, 69.	4.8	32
75	Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates Î±4 integrins. Blood, 2008, 112, 5007-5015.	1.4	31
76	Harnessing Nanomedicine for Mucosal Theranosticsâ€"A Silver Bullet at Last?. ACS Nano, 2013, 7, 2883-2890.	14.6	31
77	RNA nanomedicines: the next generation drugs?. Current Opinion in Biotechnology, 2016, 39, 28-34.	6.6	31
78	Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle, 2009, 8, 853-859.	2.6	30
79	Precision medicine â€" Delivering the goods?. Cancer Letters, 2014, 352, 2-3.	7.2	28
80	Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. Journal of Drug Targeting, 2016, 24, 780-786.	4.4	28
81	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir, 2020, 36, 13331-13341.	3.5	28
82	Structural profiling and biological performance of phospholipidâ€"hyaluronan functionalized single-walled carbon nanotubes. Journal of Controlled Release, 2013, 170, 295-305.	9.9	26
83	Detection of intestinal inflammation by MicroPET imaging using a 64Cu-labeled anti-Î²7 integrin antibody. Inflammatory Bowel Diseases, 2010, 16, 1458-1466.	1.9	25
84	Dualâ€Targeted Lipid Nanotherapeutic Boost for Chemoâ€Immunotherapy of Cancer. Advanced Materials, 2022, 34, e2106350.	21.0	25
85	RNA Inhibition Highlights Cyclin D1 as a Potential Therapeutic Target for Mantle Cell Lymphoma. PLoS ONE, 2012, 7, e43343.	2.5	24
86	Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology, 2011, 22, 494016.	2.6	23
87	Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: A mini-review. Journal of Controlled Release, 2010, 148, 63-68.	9.9	22
88	An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. Nanoscale, 2020, 12, 1894-1903.	5.6	22
89	Engineering lymphocytes with RNAi. Advanced Drug Delivery Reviews, 2019, 141, 55-66.	13.7	21
90	Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles. Journal of Controlled Release, 2021, 337, 378-389.	9.9	21

#	Article	IF	Citations
91	Harnessing RNAi nanomedicine for precision therapy. Molecular and Cellular Therapies, 2014, 2, 5.	0.2	20
92	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. Nano Letters, 2021, 21, 4774-4779.	9.1	20
93	Platelet mimicry: The emperor's new clothes?. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 245-248.	3.3	19
94	Antibody-Mediated Delivery of siRNAs for Anti-HIV Therapy. Methods in Molecular Biology, 2011, 721, 339-353.	0.9	18
95	Colitis ImmunoPET. Inflammatory Bowel Diseases, 2016, 22, 529-538.	1.9	18
96	Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. Journal of Controlled Release, 2016, 244, 149-156.	9.9	18
97	Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. Small, 2021, 17, e2100287.	10.0	18
98	SNP Detection in mRNA in Living Cells Using Allele Specific FRET Probes. PLoS ONE, 2013, 8, e72389.	2.5	17
99	Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. Cancer Letters, 2015, 365, 57-67.	7.2	17
100	Roadmap on nanomedicine. Nanotechnology, 2021, 32, 012001.	2.6	17
101	Nanotoxicity and the importance of being earnest. Advanced Drug Delivery Reviews, 2012, 64, 1661-1662.	13.7	16
102	Liposomes and other assemblies as drugs and nano-drugs: From basic and translational research to the clinics. Journal of Controlled Release, 2012, 160, 115-116.	9.9	16
103	Metastability in lipid based particles exhibits temporally deterministic and controllable behavior. Scientific Reports, 2015, 5, 9481.	3.3	16
104	ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells. Journal of Controlled Release, 2017, 257, 84-90.	9.9	16
105	Targeting central nervous system pathologies with nanomedicines. Journal of Drug Targeting, 2019, 27, 542-554.	4.4	16
106	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics, 2020, 12, 520.	4.5	16
107	The Human P-Glycoprotein Transporter Enhances the Type I Interferon Response to Listeria monocytogenes Infection. Infection and Immunity, 2015, 83, 2358-2368.	2.2	14
108	Challenges in IBD Research: Novel Technologies. Inflammatory Bowel Diseases, 2019, 25, S24-S30.	1.9	14

#	Article	IF	Citations
109	Enhanced Bioavailability of Polyaromatic Hydrocarbons in the Form of Mucin Complexes. Chemical Research in Toxicology, 2011, 24, 314-320.	3.3	13
110	Hierarchical theranostic nanomedicine: MRI contrast agents as a physical vehicle anchor for high drug loading and triggered on-demand delivery. Journal of Materials Chemistry B, 2018, 6, 1995-2003.	5.8	13
111	Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chemistry and Physics of Lipids, 2012, 165, 363-364.	3.2	12
112	Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility. ACS Nano, 2022, 16, 5246-5257.	14.6	12
113	siRNA delivery: current trends and future perspectives. Therapeutic Delivery, 2016, 7, 51-53.	2.2	11
114	RNA delivery with a human virus-like particle. Nature Biotechnology, 2021, 39, 1514-1515.	17.5	11
115	Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine, 2013, 8, 1031-1033.	3.3	10
116	Molecular and Cellular Therapies: New challenges and opportunities. Molecular and Cellular Therapies, 2013, 1, 1.	0.2	10
117	Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. Molecular Therapy, 2017, 25, 5-7.	8.2	10
118	Integrin-Targeted Nanoparticles for siRNA Delivery. Methods in Molecular Biology, 2011, 757, 497-507.	0.9	10
119	RNAi nanoparticles in the service of personalized medicine. Nanomedicine, 2009, 4, 853-855.	3.3	9
120	Targeting Anthracycline-Resistant Tumor Cells with Synthetic Aloe-Emodin Glycosides. ACS Medicinal Chemistry Letters, 2011, 2, 528-531.	2.8	9
121	Structural Characterization of the Drug Translocation Path of MRP1/ABCC1. Israel Journal of Chemistry, 2014, 54, 1382-1393.	2.3	9
122	Fe₃O₄ Nanoparticles and Paraffin Wax as Phase Change Materials Embedded in Polymer Matrixes for Temperature-Controlled Magnetic Hyperthermia. ACS Applied Nano Materials, 2021, 4, 11187-11198.	5.0	9
123	Delivery strategies of RNA therapeutics to leukocytes. Journal of Controlled Release, 2022, 342, 362-371.	9.9	9
124	Focus on RNA interference: from nanoformulations toin vivodelivery. Nanotechnology, 2018, 29, 010201.	2.6	6
125	A tissue chamber chip for assessing nanoparticle mobility in the extravascular space. Biomedical Microdevices, 2019, 21, 41.	2.8	5
126	Integrin-Targeted Stabilized Nanoparticles for an Efficient Delivery of siRNAs In Vitro and In Vivo. Methods in Molecular Biology, 2012, 820, 105-116.	0.9	4

#	Article	IF	Citations
127	Featuring the special issue guest editor: Dan Peer, Ph.D. Cancer Letters, 2014, 352, 1.	7.2	4
128	Zooming in on selectins in cancer. Science Translational Medicine, 2016, 8, 345fs11.	12.4	4
129	Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. Methods in Molecular Biology, 2019, 1974, 151-159.	0.9	4
130	Personalized Tissue Implants: Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants (Adv. Mater. 1/2019). Advanced Materials, 2019, 31, 1970007.	21.0	4
131	IKAP/hELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression. Cell Adhesion and Migration, 2010, 4, 541-550.	2.7	3
132	RNA Delivery: A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes (Adv.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	21.0	3
133	RNA interference-based therapeutics and diagnostics. Drug Delivery and Translational Research, 2014, 4, 1-2.	5.8	2
134	Dielectrophoretic characterization of cells in a stationary nanoliter droplet array with generated chemical gradients. Biomedical Microdevices, 2015, 17, 91.	2.8	2
135	Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles. Nano Futures, 2018, 2, 045003.	2.2	2
136	Dualâ€Targeted Lipid Nanotherapeutic Boost for Chemoâ€Immunotherapy of Cancer (Adv. Mater. 13/2022). Advanced Materials, 2022, 34, .	21.0	2
137	T.86. siRNA Delivery with Integrin LFA-1-targeted Nanoparticles Prevents HIV Infection in Humanized Mice. Clinical Immunology, 2009, 131, S75-S76.	3.2	1
138	Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. Therapy: Open Access in Clinical Medicine, 2009, 6, 293-296.	0.2	1
139	Themed issue on nanoparticles in biology. Journal of Materials Chemistry B, 2013, 1, 5174.	5.8	1
140	Targeting Cancer Using Nanocarriers. Advances in Delivery Science and Technology, 2016, , 131-155.	0.4	1
141	Extrahepatic delivery of RNA to immune cells. , 2022, , 57-86.		1
142	Sweet Fairytale: Carbohydrates as Backbones for Glyconanomedicine. Israel Journal of Chemistry, 2013, 53, 616-629.	2.3	0
143	Gene Silencing in the Right Place at the Right Time. Molecular Therapy, 2018, 26, 2539-2541.	8.2	0
144	Reprogramming the lymphocyte axis for advanced immunotherapy. Advanced Drug Delivery Reviews, 2019, 141, 1-2.	13.7	0

#	Article	IF	Citations
145	Gene Silencing: Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer (Small 19/2021). Small, 2021, 17, 2170086.	10.0	0
146	Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies. , 2022, , 117-146.		0
147	Nanomedicines for Systemic Delivery of RNAi Therapeutics. Advances in Delivery Science and Technology, 2013, , 127-142.	0.4	0
148	RNAi Nanomedicines toward Advancing Personalized Medicine. , 2014, , 59-79.		0